# VIP (aviptadil) IV in critical COVID-19 respiratory failure

Source: https://pepvault.app/research/vip-youssef-2022

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [VIP](https://pepvault.app/research#vip)

Randomized trial · people

# VIP (aviptadil) missed its main goal in critical COVID-19 trial

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In critical COVID-19, IV VIP did not beat placebo on the trial's main outcome, though survival looked better; it says nothing about other uses of VIP.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 196
- **Published:** 2022
- **Journal:** Crit Care Med

## What they tested

The team tested whether aviptadil, a synthetic form of VIP given by IV, could help patients with COVID-19 respiratory failure survive and recover better than placebo.

## How the study was done

A randomized, placebo-controlled trial at 10 U.S. hospitals in 196 patients with COVID-19 respiratory failure. Patients were assigned 2:1 to 3 days of IV aviptadil or placebo (a dummy infusion) and followed for 60 days.

<!--promo-->

PepVault for iPhone

## Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

The main goal was being alive and free of respiratory failure at day 60, and aviptadil fell short: its OR (odds ratio, which compares the chance of an outcome on the drug with the chance on placebo) was 1.6, with a 95% CI of 0.86-3.11, so there was no clear difference from placebo. Survival alone at day 60 was better with aviptadil (OR 2.0; 95% CI 1.1-3.9; p = 0.035), and by day 3 the respiratory distress ratio improved and interleukin 6, an inflammation signal, fell (p = 0.02). In subgroups, patients on high-flow nasal oxygen at the start were more likely to reach the main goal (p = 0.039), and those on mechanical ventilation had 10-fold higher odds of survival with the drug (p = 0.031); the team saw no drug-related serious side effects.

## What it doesn’t show

The trial failed its main outcome, so the survival and subgroup results are secondary findings that can't settle the question alone. It studied only hospitalized patients with critical COVID-19 who got a short IV course.

## The paper

Youssef et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022.

- [PubMed (PMID 36044317)](https://pubmed.ncbi.nlm.nih.gov/36044317/)
- [The paper (DOI 10.1097/CCM.0000000000005660)](https://doi.org/10.1097/CCM.0000000000005660)
- [ClinicalTrials.gov (NCT04311697)](https://clinicaltrials.gov/study/NCT04311697)

## The compound

- [VIP: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/vip)
- [VIP dose guide](https://pepvault.app/lab/dosage/vip)

## With this study

### VIP

- [VIP: the full reference](https://pepvault.app/peptides/vip)
- [VIP dose guide](https://pepvault.app/lab/dosage/vip)

### Studies

- [VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19](https://pepvault.app/research/vip-esendagli-2025)
- [VIP fragment VIP10-28 boosted, not blocked, skin vessel widening](https://pepvault.app/research/vip-wilkins-2005)
- [All 5 studies](https://pepvault.app/research#vip)

### Compared with

- [BPC-157 vs VIP](https://pepvault.app/peptides/compare/bpc-157-vs-vip)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on VIP

- [VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19](https://pepvault.app/research/vip-esendagli-2025) Randomized trial · people · 2025
- [VIP fragment VIP10-28 boosted, not blocked, skin vessel widening](https://pepvault.app/research/vip-wilkins-2005) Clinical trial · people · 2005
- [VIP: peak flow rose 26 l/min in severe asthma, less than salbutamol](https://pepvault.app/research/vip-morice-1986) Clinical trial · people · 1986
- [VIP: tear levels rose after laser eye surgery, peaking at 1 week](https://pepvault.app/research/vip-kang-2023) Observational study · people · 2023
- [Every study on VIP](https://pepvault.app/research#vip)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### VIP

- [VIP: the full reference](https://pepvault.app/peptides/vip)
- [VIP dose guide](https://pepvault.app/lab/dosage/vip)

### Studies

- [VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19](https://pepvault.app/research/vip-esendagli-2025)
- [VIP fragment VIP10-28 boosted, not blocked, skin vessel widening](https://pepvault.app/research/vip-wilkins-2005)
- [All 5 studies](https://pepvault.app/research#vip)

### Compared with

- [BPC-157 vs VIP](https://pepvault.app/peptides/compare/bpc-157-vs-vip)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on VIP](https://pepvault.app/research#vip)

## The library

- [VIP](https://pepvault.app/peptides/vip)
- [VIP dose guide](https://pepvault.app/lab/dosage/vip)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
